JP2022537415A - Ｆｇｆｒ４を阻害するための化合物 - Google Patents

Ｆｇｆｒ４を阻害するための化合物 Download PDF

Info

Publication number
JP2022537415A
JP2022537415A JP2021576063A JP2021576063A JP2022537415A JP 2022537415 A JP2022537415 A JP 2022537415A JP 2021576063 A JP2021576063 A JP 2021576063A JP 2021576063 A JP2021576063 A JP 2021576063A JP 2022537415 A JP2022537415 A JP 2022537415A
Authority
JP
Japan
Prior art keywords
alkyl
compound
pharmaceutically acceptable
acceptable salt
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021576063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537415A5 (enExample
Inventor
シュー，インジー
アンソニー ロメロ，エフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terns Pharmaceuticals Inc
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of JP2022537415A publication Critical patent/JP2022537415A/ja
Publication of JP2022537415A5 publication Critical patent/JP2022537415A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021576063A 2019-06-21 2020-06-18 Ｆｇｆｒ４を阻害するための化合物 Pending JP2022537415A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962864883P 2019-06-21 2019-06-21
US62/864,883 2019-06-21
PCT/US2020/038541 WO2020257527A1 (en) 2019-06-21 2020-06-18 Compounds for inhibiting fgfr4

Publications (2)

Publication Number Publication Date
JP2022537415A true JP2022537415A (ja) 2022-08-25
JP2022537415A5 JP2022537415A5 (enExample) 2024-01-17

Family

ID=74037325

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021576063A Pending JP2022537415A (ja) 2019-06-21 2020-06-18 Ｆｇｆｒ４を阻害するための化合物

Country Status (7)

Country Link
US (1) US20220362245A1 (enExample)
EP (1) EP3986405A4 (enExample)
JP (1) JP2022537415A (enExample)
CN (1) CN114144176A (enExample)
AU (1) AU2020298246A1 (enExample)
CA (1) CA3144366A1 (enExample)
WO (1) WO2020257527A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116003400B (zh) * 2021-10-22 2025-05-02 暨南大学 2-甲酰基四氢萘啶类化合物及其药用组合物和应用
CN114835640B (zh) * 2022-05-24 2024-02-13 中国药科大学 成纤维细胞生长因子受体抑制剂、制备方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015059668A1 (en) * 2013-10-25 2015-04-30 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
CN108341815A (zh) * 2017-01-25 2018-07-31 上海喆邺生物科技有限公司 一种抑制激酶化合物及其用途
CN109745321A (zh) * 2017-11-08 2019-05-14 上海翰森生物医药科技有限公司 包含fgfr4抑制剂的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9802917B2 (en) * 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
WO2017164705A1 (ko) * 2016-03-24 2017-09-28 재단법인 대구경북첨단의료산업진흥재단 신규한 피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 fgfr 관련 질환의 예방 또는 치료용 약학적 조성물
CN113105454B (zh) * 2016-05-20 2022-10-11 江苏豪森药业集团有限公司 Fgfr4抑制剂、其制备方法和应用
CN109563091B (zh) * 2016-08-12 2022-04-29 江苏豪森药业集团有限公司 Fgfr4抑制剂及其制备方法和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015059668A1 (en) * 2013-10-25 2015-04-30 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
CN108341815A (zh) * 2017-01-25 2018-07-31 上海喆邺生物科技有限公司 一种抑制激酶化合物及其用途
CN109745321A (zh) * 2017-11-08 2019-05-14 上海翰森生物医药科技有限公司 包含fgfr4抑制剂的药物组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ACS MEDICINAL CHEMISTRY LETTERS, vol. 9(3), JPN6024025664, 2018, pages 215 - 220, ISSN: 0005360860 *

Also Published As

Publication number Publication date
EP3986405A1 (en) 2022-04-27
AU2020298246A1 (en) 2022-01-27
EP3986405A4 (en) 2023-06-14
US20220362245A1 (en) 2022-11-17
WO2020257527A1 (en) 2020-12-24
CN114144176A (zh) 2022-03-04
CA3144366A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
US9757364B2 (en) Naphthyridine derivative compounds
JP6473133B2 (ja) Ｋｒａｓｇ１２ｃの共有結合性阻害剤
TWI761315B (zh) 醫藥化合物
JP2022106967A (ja) 癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体
JP7213804B2 (ja) αＶインテグリンアンタゴニストとしてのインダゾール誘導体
ES2791179T3 (es) Derivados de piridopirazina y naftiridina para el tratamiento del cáncer
KR20220130168A (ko) 피리미딘-4(3h)-케톤 헤테로시클릭 화합물, 그의 제조 방법, 및 의약 및 약리학에서의 그의 용도
JP2023510929A (ja) ヘテロアリール誘導体、その製造方法およびその使用
CN112469720B (zh) 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
CN115835866B (zh) Cereblon结合化合物、其组合物及其用于治疗的方法
JP2020504715A (ja) Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物およびその使用方法
KR20160142316A (ko) 마크로사이클릭 피리미딘 유도체
CN113454081A (zh) 咪唑并吡啶基化合物及其用于治疗增生性疾病的用途
JP2019515932A (ja) チロシンキナーゼｂｃｒ−ａｂｌ阻害剤としての新規複素環化合物
JP2026502215A (ja) Ｐｒｍｔ５－ｍｔａ阻害剤
JP2022537415A (ja) Ｆｇｆｒ４を阻害するための化合物
TW202100514A (zh) 芳香族衍生物其製備方法和醫學用途
EP4293029A1 (en) Azaheteroaryl compound, preparation method therefor, and application thereof
CN117396463A (zh) 用于预防或治疗癌症的苯甲酰胺衍生物、其制备方法和含有其作为活性成分的药物组合物
JP2019518032A (ja) Ｐｉ３ｋ ｂｅｔａ阻害薬としての二環式ピリジン、ピラジンおよびピリミジン誘導体
CN103319456B (zh) 二氢吡啶类化合物、其组合物、制备方法和用途
WO2023239846A1 (en) Heterocyclic compounds as pi3kα inhibitors
TW202540096A (zh) 靶向降解雄激素受體的雙功能嵌合體的雜環化合物及其用途
HK40058867A (en) Imidazopyridinyl compounds and use thereof for treatment of proliferative disorders
BR122024027333A2 (pt) Compostos heterocíclicos inibidores do bromodomínio de cbp/ep300, composição farmacêutica que compreende os mesmos e uso destes para o tratamento de doença ou distúrbio mediado por cbp e/ou ep300

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241001

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241224